We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| 4d Pharma Plc | LSE:DDDD | London | Ordinary Share | GB00BJL5BR07 | ORD 0.25P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 16.36 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMDDDD
RNS Number : 9296D
4d Pharma PLC
01 July 2019
4D PHARMA PLC
("4D", the "Company" or, together with its subsidiaries, the "Group")
Appointment of N+1 Singer as Nominated Adviser & Joint Broker
4D pharma plc (AIM: DDDD), a pharmaceutical company focusing on the development of live biotherapeutics, is pleased to announce the appointment of N+1 Singer as Nominated Adviser and Joint Broker with immediate effect. Bryan Garnier & Co. Limited will remain as Joint Broker.
End
Enquiries
4D pharma plc + 44 (0)113 895 Duncan Peyton, Chief Executive Officer 0130 Fay Weston, Head of Investor Relations + 44 (0)7990 381713 N+1 Singer (Nominated Adviser & Joint Broker) Aubrey Powell, Justin McKeegan, Alex Bond (Corporate Finance) +44 (0) 20 7496 Tom Salvesen (Corporate Broking) 3000 Bryan Garnier & Co. Limited - Joint Broker Dominic Wilson / Phil Walker +44 (0)20 7332 2500
About 4D
Founded in February 2014, 4D is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform that rationally identifies novel bacteria based on a deep understanding of function and mechanism. 4D's Live Biotherapeutic products are orally delivered single strains of bacteria that are naturally found in the healthy human gut. 4D has three clinical studies in progress, namely a Phase II clinical study of Blautix(R) in Irritable Bowel Syndrome, a Phase I/II study of MRx0518 in combination with KEYTRUDA(R) (pembrolizumab) in solid tumours and a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumours. Other focus programmes include disease areas such as asthma and CNS disease.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
APPFMMPTMBBJBTL
(END) Dow Jones Newswires
July 01, 2019 02:01 ET (06:01 GMT)
1 Year 4d Pharma Chart |
1 Month 4d Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
